Duloxetine in the treatment of major psychiatric and neuropathic disorders

Expert Review of Neurotherapeutics

Volumn 8, Issue 4, 2008, Pages 527-536

  Müller, Norbert ^a   Schennach, Rebecca ^a   Riedel, Michael ^a   Möller, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anxiety; Depression; Duloxetine; Incontinence; Pain

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIABETIC NEUROPATHY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; MAJOR DEPRESSION; MENTAL DISEASE; NAUSEA; NEUROPATHY; PAIN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PULSE RATE; QT INTERVAL; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STRESS INCONTINENCE; SWEATING; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANXIETY; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICIAN'S PRACTICE PATTERNS; THIOPHENES; TREATMENT OUTCOME; URINARY INCONTINENCE, STRESS;

EID: 42249098854     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.4.527     Document Type: Review

References (96)

1. Davidson JR, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J. Clin. Psychiatry 60(Suppl. 7), 4-9; discussion 10-11 (1999).
2. Greden JF. The burden of recurrent depression: causes, consequences, and future prospects. J. Clin. Psychiatry 62(Suppl. 22), 5-9 (2001).
3. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 61(Suppl. 6), 4-6 (2000).
4. Schildkraut JJ. The catecholamine hypothesis of affective disorders. A review of supporting evidence. Int. J. Psychiatry 4(3), 203-217 (1967).
5. Stahl SM. The psychopharmacology of painful physical symptoms in depression. J. Clin. Psychiatry 63(5), 382-383 (2002).
6. Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J. Gen. Intern. Med. 19(8), 813-818 (2004).
7. Bauer M, Möller H-J, Schneider E. Duloxetine: a new selective and dual-acting antidepressant. Expert Opin. Pharmacother. 7(4), 421-427 (2006). • Presents a good summary of duloxetine's treatment efficacy, safety and tolerability.
8. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8(1), 23-33 (1993).
9. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25(6), 871-880 (2001).
10. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340(2-3), 249-258 (1997).
11. Koch S, Hemrick-Luecke SK, Thompson LK et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45(7), 935-944 (2003).
12. Richelson E. The clinical relevance of antidepressant interaction with neurotransmitter transporters and receptors. Psychopharmacol. Bull. 36(4), 133-150 (2002).
13. Cymbalta® (duloxetine), prescribing information. Eli Lilly and company. Indianapolis, IN, USA (2005).
14. Sharma A, Goldberg MJ, Cerimele BJ Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J. Clin. Pharmacol. 40(2), 161-167 (2000).
15. Barkin RL, Barkin S. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am. J. Ther. 12(5), 431-438 (2005).
16. Skinner MH, Kuan HY, Pan A et al. Duloxetine in both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther. 57, 54-61 (2003).
17. Lantz RJ, Gillespie TA, Rash TJ et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Dispos. 31(9), 1142-1150 (2003). • Presents a good summary of duloxetine's pharmakokinetics.
18. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J. Psychiatr. Res. 39(1), 43-53 (2005).
19. Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry 63(4), 308-315 (2002).
20. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J. Psychiatr. Res. 36(6), 383-390 (2002).
21. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. 14(6), 457-470 (2004).
22. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiatry 63(3), 225-231 (2002).
23. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacol. 24(4), 389-399 (2004).
24. Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Tran PV. Duloxetine: a new treatment for the emotional and physical symptoms of depression. Primary Care Companion J. Clin. Psychiatry 5, 19-28 (2003).
25. Perahia DGS, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Psychiatry 21, 367-378 (2006).
26. Hudson JI, Perahia DG, Gilaberte I, Wang F, Watkin JG. Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatry 7, 43 (2007).
27. Pigott T, Prakash A, Arnold L, Aaronson S, Mallinckrodt CH, Wohlreich MM. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr. Med. Res. Opin. 6, 1303-1318 (2007). • A placebo and selective serotonin reuptake inhibitor-controlled, double-blinded trial with an 8-month follow-up.
28. Hamilton M. The Hamilton rating scale for depression. In: Assessment of Depression. Sartorius N, Ban TA (Eds). Springer, Berlin, Germany, 143-152 (1986).
29. Hirschfeld RM, Vornik LA. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J. Clin. Psychiatry 65(Suppl. 4), 46-52 (2004).
30. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr. Med. Res. Opin. 7, 1605-1614 (2007).
31. Wohlreich MM, Mallinckrodt CH, Watkin JG, Hay DP. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr. 7(4), 11 (2004). • Worthwhile article evaluating duloxetine in the elderly with a 52-week follow-up.
32. Cookson J, Gilaberte I, Desaiah D, Kajdasz DK. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int. Clin. Psychopharmacol. 21(5), 267-273 (2006).
33. Thase M, Lu Y, Joliat M, Detke M. Remission rates in double-blind, placebo-controlled clinical trials of duloxetine with SSRI as a comparator. Eur. Neuropsychopharmacol. (Suppl.), S259 (2003).
34. Swindle RW, Rosenbaum JR, Mallinckrodt CH et al. Efficacy of duloxetine treatment group: analysis of pooled data from six placebo-controlled clinical trials. Int. J. Neuropsychopharmacol. 7(Suppl. 1), P02.177 (2004).
35. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiatry 64 (10), 1237-1244 (2003). • One of the few articles presenting data on long-term duloxetine treatment.
36. Eckert L, Lancon C. Duloxetine compared with fluoxetine and venlafaxine: use of metaregresion analysis for indirect comparison. BMC Psychiatry 24, 6-30 (2006).
37. Vis P. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann. Clin. Psychiatry 39, 1798-1807 (2005).
38. Hansen RA, Gartlehner G, Lohr KN, Gayes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann. Intern. Med. 143, 415-426 (2005).
39. Perahia DG, Pritchett YL, Kajdasz DK et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J. Psychiatr. Res. 42(1), 22-34 (2007).
40. Simon GE, Von Korff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N. Engl. J. Med. 341(18), 1329-1335 (1999).
41. Posse M, Hallstrom T. Depressive disorders among somatizing patients in primary health care. Acta Psychiatr. Scand. 98(3), 187-192 (1998).
42. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch. Intern. Med. 163, 2433-2445 (2003).
43. Fava M, Mallinckrodt CH, Detke Mj et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry 65, 521-530 (2004).
44. Desarkar P, Das A, Sinha V. Duloxetine for childhood depression with pain and dissociative symptoms. Eur. Child Adolesc. Psychiatry 15(8), 496-499 (2006). • First data on the efficacy and tolerability of duloxetine in children.
45. Meighen KG. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. J. Child Adolesc. Psychopharmacol. 17(1), 121-127 (2007). • First data on the efficacy and tolerability of duloxetine in children.
46. Mogotsi M, Kaminer D, Stein DJ. Quality of life in anxiety disorders. Harv. Rev. Psychiatry 8, 273-282 (2000).
47. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatrics Press, Inc. Washington, DC, USA (1994).
48. Hartford J, Kornstein S, Liebowitz MR et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial Int. Clin. Psychopharmacol. 22(3), 167-174 (2007). • One of the three trials examining duloxetine's efficacy in generalised anxiety disorder.
49. Koponen H, Allgulander C, Erickson J et al. Efficacy of duloxetine for treatment of generalized anxiety disorder: implications for primary care physicians. Prim. Care Companion J. Clin. Psychiatry 9(2), 100-107 (2007).
50. Rynn M, Russell KM, Erickson J et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress. Anxiety (2007) (Epub ahead of print).
51. Endicott J, Russell J, Raskin J et al. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies J. Clin. Psychiatry 68, 518-524 (2007).
52. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet. Med. 21, 976-982 (2004).
53. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity and impact on painful diabetic peripheral neuropathy in Type 2 diabetes. Diabetes Care 29, 1518-1522 (2006).
54. Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav. Brain Sci. 20, 404-419 (1997).
55. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 116, 109-118 (2005).
56. Raskin J, Pritcchett YL, Wang F et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 6, 346-356 (2005).
57. Wernicke JF, Pritchett YL, D'Souza DN et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67, 1411-1420 (2006).
58. Ziegler D, Pritchett YL, Wang F et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care 30, 664-669 (2007).
59. Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJM. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 30, 21-26 (2007).
60. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin. Drug Saf. 5, 157-168 (2006).
61. Lembo G, Capaldo B, Rendina V et al. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am. J. Physiol. 266, E242-E247 (1994).
62. Wernicke JF, Rosen AS, Pritchett YL, Souza DN, Westell DJ, Arnold LM. Duloxetine in the treatment of women with fibromyalgia. Presented at: The 158th Annual Meeting of the American Psychiatric Association. Atlanta, GA, USA 21-26 May 2005 (NR860).
63. Arnold LM, Lu Y, Crofford LJ et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 50, 2974-2984 (2004). • Study demonstrating the safety and efficacy of duloxetine to improve fibromyalgia independent of the presence of major depressive disorder.
64. Rooks DS. Fibromyalgia treatment update. Curr. Opin. Rheumatol. 19, 111-117 (2007).
65. Hampel C, Artibani W, Espuna Pons M et al. Understanding the burden of stress urinary incontinence in Europe: a qualitative review of the literature. Eur. Urol. 46(1), 15-27 (2004).
66. Kinchen KS, Burgio K, Diokno AC, Fultz NH, Bump RC. Burden of stress urinary incontinence for community-dwelling women. Am. J. Obstet. Gynecol. 189, 1275-1282 (2003).
67. Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int. 93, 324-330 (2004).
68. Boy S, Reitz A, Wirth B et al. Facilitatory neuromodulative effect of duloxetine on pudendal motor neurons controlling the urethral pressure: a functional urodynamic study in healthy women. Eur. Urol. 50(1), 119-125 (2006).
69. Athanasiou S, Chaliha C, Digesu GA et al. The effects of duloxetine on urethral function and spincter morphology. Int. Urogynecol. J. Pelvic Floor Dysfunct. 18(7), 763-767 (2006).
70. Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology 62(4 Suppl. 1), 3-9 (2003).
71. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J. Pharmacol. Exp. Ther. 274(2), 1014-1024 (1995).
72. Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet. Gynecol. 104(3), 511-519 (2004).
73. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J. Urol. 170(4 Part 1), 1259-1263 (2003). • Worthwhile summary on pharmacological treatment in stress urinary incontinence.
74. Ghoniem GM, Van Leeuwen JS, Elser DM et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J. Urol. 173(5), 1647-1653 (2005).
75. Kinchen KS, Obenchain R, Swindle R. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. Int. Urogynecol. J. Pelvic Floor Dysfunct. 16(5), 337-344 (2005).
76. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int. 93(3), 311-318 (2004).
77. Mulcahy JJ, Laddu AR, Faries DE et al. Efficacy and safety of duloxetine in stress incontinence patients. Neurourol. Urodyn. 15, 395-396 (1996).
78. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine Urinary Incontinence Study Group: duloxetine versus placebo in the treatment of stress urinary incontinence. Am. J. Obstet. Gynecol. 187(1), 40-48 (2002).
79. van Kerrebroeck P, Abrams P, Lange R et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 111(3), 249-257 (2004).
80. Zinner N, Sarshik S, Yalcin I et al. Evaluation of various efficacy measures from 140 stress and 146 mixed incontinence patients enrolled in a double-blind, placebo-controlled trial of duloxetine. In: Proceedings of International Continence Society. 175-176 (1998).
81. Penson DF, McLerran D, Feng Z et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J. Urol. 173(5), 1701-1705 (2005).
82. Imamoglu MA, Tuygun C, Bakirtas H, Yigitbasi O, Kiper A. The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. Eur. Urol. 47(2), 209-213 (2005).
83. Schlenker B, Gratzke CH, Reich O, Schorsch I, Seitz M, Stief CG. Preliminary results on the off-label use of duloxetine for the treatment of stres incontinence after radical prostatectomy or cystectomy. Eur. Urol. 49, 1075-1078 (2006). • First results on off-label use of duloxetine in incontinence after urological surgery.
84. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr. Pharm. Des.11(12), 1475-1493 (2005). • Presents a worthwhile review of duloxetine's pharmacology and pharmacokinetics.
85. Greist J, McNamara RK, Mallickrodt CH et al. Incidence and duration of antidepressant-induceded nausea: duloxetine compared with paroxetine and fluoxetine. Clin. Ther. 26, 1446-1455 (2004).
86. Thase ME, Tran PV, Wiltse C et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J. Clin. Psychopharmacol. 25, 132-140 (2005).
87. Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 30(5), 427-455 (2007). •• Very valid evaluation of the cardiovascular safety profile.
88. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J. Clin. Psychopharmacol. 8(5), 323-330 (1988).
89. Raskin J, Goldstein DJ, Mallickrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiatry 64, 1237-1244 (2003).
90. Wise TN, Perahia DGS, Pangallo BRN, Losin WG, Wiltse CG. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim. Care Companion. J. Clin. Psychiatry 8(5), 269-278 (2006).
91. Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J. Clin. Psychiatry 62(Suppl. 3), 22-34 (2001).
92. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol. 19(1), 67-85 (1999).
93. Brannan SK, Detke MJ, Wang F, Mallinckrodt CH, Tran PV, Delgado PL. Comparison of sexual functioning in patients receiving duloxetine of paroxetine: acute - and long-term data. Presented at: The 156th American Psychiatric Association Meeting. San Francisco, CA, USA, 17 May, 2003 (Abstract NR477).
94. Delgado P, Brannan S, Mallickrodt CH et al. Sexual functioning assessed in 4 doubleblind placebo - and paroxetin-controlled trials of duloxetine for major depressive disorder. J. Clin. Psychiatry 66, 686-692 (2005).
95. Hudson JI, Wohlreich MW, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum. Psychopharmacol. Clin. Exp. 20, 327-341 (2005).
96. National Collaborating Centre for Women's and Children's Health: urinary incontinence - the management of urinary incontinence in women. NICE clinical guideline 40. October 2006. www.nice.org.uk/nicemedia/pdf/CG40imp lementationadvice.doc